The first-in-human trial saw all three patients able to increase their walking distance within six minutes to 20 meters.

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...

More research is needed to confirm gray matter, the darker tissue found in the brain and spinal cord, “as a potential disease ...

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

A woman with SMA type 3 became pregnant while on Spinraza treatment and gave birth to a healthy child, per a case report.

Novartis has revealed top-line results from the phase 3 STEER study, which involved treatment-naïve patients with SMA type 2 aged from two to 17 who can sit, but who have never walked independently.

Health activists demand government action to reduce the cost of SMA medicines, citing constitutional obligations and ...

Opens in a new tab or window Researchers evaluated oxygen saturation and arterial CO2 variables to screen for sleep disordered breathing in children with SMA type 1-3. Of the measures evaluated ...

Intrathecal onasemnogene abeparvovec improved HFMSE scores in patients with SMA type 2, indicating enhanced motor function. The STEER study confirmed the therapy's favorable safety profile ...

Novartis has reported positive topline outcomes from the Phase III STEER trial of an ... in treating individuals with spinal muscular atrophy (SMA) Type 2. The randomised, sham-controlled study ...